Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03715452 · ClinicalTrials.gov registry record

DyeVert™ Plus Contrast Reduction System Multicenter Observational Study

A clinical trial of Chronic Kidney Disease, sponsored by Osprey Medical.

Completed
Registry status
114
Enrollment target
8
Study locations

NCT03715452: Completed study of Chronic Kidney Disease, sponsored by Osprey Medical.

NCT03715452 is a study of Chronic Kidney Disease that has completed, run by Osprey Medical. The registered enrollment target is 114 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03715452, a study of Chronic Kidney Disease, has completed, sponsored by Osprey Medical.

COMPLETED
Registry status
114 participants
Enrollment target
8
Study locations

Study Summary

This is a prospective, single arm, multi-center, observational clinical study of the DyeVert Plus System. The DyeVert Plus System is an FDA-cleared device designed to reduce contrast media volume delivered during angiography and permit real-time contrast media volume monitoring.

Primary Outcome

The percentage of contrast media volume saved (diverted) over the total procedure as reported on the DyeVert Plus display at the end of each case.

Conditions Studied

Interventions

  • DEVICE DyeVert Plus Contrast Reduction System

Study Locations (8)

California

  • Harbor UCLA Medical Center - Torrance

Georgia

  • Atlanta VA Medical Center, Emory University School of Medicine - Atlanta

Illinois

  • University of Chicago Medical Center - Chicago

Michigan

  • William Beaumont Hospital - Royal Oak

Mississippi

  • North Mississippi Medical Center - Tupelo

Missouri

  • Washington University School of Medicine - St Louis

North Carolina

  • WakeMed Heart and Vascular - Raleigh

Ohio

  • Christ Hospital, Heart and Vascular Center, Lindner Research Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2017-07-01
Est. Completion 2018-03-30
Osprey Medical

3 total trials

What the finished NCT03715452 record still lists

NCT03715452 is an observational study that tracks outcomes without assigning an intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which DyeVert Plus Contrast Reduction System is the first listed.

NCT03715452 lists 8 locations in 8 states (California, Georgia, Illinois).

Frequently Asked Questions

What is clinical trial NCT03715452 about?

NCT03715452 is a clinical study titled "DyeVert™ Plus Contrast Reduction System Multicenter Observational Study". This is a prospective, single arm, multi-center, observational clinical study of the DyeVert Plus System. The DyeVert Plus System is an FDA-cleared device designed to reduce contrast media volume delivered during angiography and permit real-time contrast media volume monitoring.

What is the current status of trial NCT03715452?

This trial is currently completed. The enrollment target is 114 participants. The study started on 2017-07-01. Estimated completion is 2018-03-30.

What conditions does trial NCT03715452 study?

This clinical trial studies the following conditions: Chronic Kidney Disease.

What interventions are being tested in trial NCT03715452?

The interventions under investigation include: DyeVert Plus Contrast Reduction System (DEVICE).

Who is sponsoring clinical trial NCT03715452?

This trial is sponsored by Osprey Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03715452 being conducted?

This trial has 8 study locations across California, Georgia, Illinois, Michigan, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03715452's enrollment target sits among peer trials

114 53rd of 101 higher than 49 of 101 other Chronic Kidney Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04522791 · 114 participants · Phase 2

    Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)

  • NCT04875052 · 114 participants · NA

    Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury

  • NCT05100342 · 114 participants

    Prospective Validation of a Points Score System Predicting 30-day Survival

  • NCT05224089 · 114 participants · Phase 4

    Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03715452, the US trial registry maintained by the National Library of Medicine. NCT03715452 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.